Cognition Therapeutics (NASDAQ:CGTX) is a clinical‐stage biopharmaceutical company headquartered in Pittsburgh, Pennsylvania, that specializes in developing novel small‐molecule therapies for neurodegenerative diseases. Founded in 2006 as a spin‐out from the University of Pittsburgh, the company has built a proprietary platform targeting synaptic dysfunction and toxic protein aggregates, with a primary focus on Alzheimer’s disease and related dementias. Its research and development team operates from state‐of‐the‐art facilities in the U.S., leveraging both in‐house discovery efforts and strategic academic collaborations to advance its pipeline.
The company’s lead candidate, CT1812, is an oral small‐molecule modulator of the Sigma‐2 receptor complex designed to displace toxic amyloid oligomers from neuronal synapses and restore synaptic function. CT1812 has completed Phase IIa clinical studies in mild‐to‐moderate Alzheimer’s disease, demonstrating favorable safety and target engagement, and is now being evaluated in additional expansion cohorts. In parallel, Cognition Therapeutics is exploring CT1812’s potential in dementia with Lewy bodies and other synaptopathies, as well as advancing next‐generation molecules aimed at improving blood–brain barrier penetration and pharmacokinetic profiles.
Under the leadership of a seasoned management team with decades of combined experience in neuroscience and drug development, Cognition Therapeutics has established partnerships with academic institutions and consortia to support clinical trial execution and biomarker development. The company’s board and scientific advisory panel include experts in neurology, pharmacology, and translational medicine, reflecting its commitment to rigorous science and unmet medical need.
Serving patients and healthcare stakeholders in North America and Europe, Cognition Therapeutics is committed to pioneering treatments that address the underlying mechanisms of neurodegeneration. With a robust intellectual property portfolio and a disciplined approach to clinical advancement, the company aims to deliver first‐in‐class therapeutic options that can alter the course of Alzheimer’s disease and related disorders.
